160 Participants Needed

Apollo Device for Scleroderma

(ASScERT-QoL Trial)

RT
MM
Overseen ByMaureen M Laffoon, BS
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Robyn T. Domsic, MD, MPH
Must be taking: Immunosuppressives, Vasodilators
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a wearable device called the Apollo Neuro to determine its effectiveness in helping people with systemic sclerosis (SSc) manage symptoms like fatigue and Raynaud phenomenon, which causes cold and numb fingers. Participants will receive either the real device or a sham (inactive) device to compare results. The study aims to improve symptom management and quality of life for those with SSc. Suitable candidates have been diagnosed with SSc, experience fatigue and Raynaud phenomenon, and regularly use a smartphone. As an unphased trial, this study offers participants the opportunity to contribute to innovative research that could enhance symptom management for SSc.

Will I have to stop taking my current medications?

You can continue taking your current medications if they are immunosuppressive drugs, vasodilators, or medications for pulmonary hypertension, antidepressants, and anxiolytics, as long as you've been on a steady dose for 4 weeks before starting the trial. However, you cannot be on beta-blockers, sedatives, hypnotics, opioids, benzodiazepines, or anti-psychotic medications.

What prior data suggests that the Apollo Neuro device is safe for Scleroderma patients?

Research has shown that the Apollo Neuro device is generally safe and easy to use. In earlier studies, participants who used the Apollo wearable for four weeks reported feeling less tired and experiencing fewer Raynaud's attacks, common issues for those with systemic sclerosis. Importantly, these studies did not find any major side effects, indicating the device's safety. Current evidence suggests that the Apollo device is a promising way to manage symptoms without causing harm.12345

Why are researchers excited about this trial?

Most treatments for scleroderma, like immunosuppressants and anti-fibrotic drugs, work by slowing down the immune system or reducing tissue thickening. However, the Apollo Neuro Device is different because it uses gentle vibrations to help regulate the nervous system, aiming to reduce stress and improve overall well-being. This is a non-invasive method that doesn't involve drugs, which could mean fewer side effects compared to traditional medications. Researchers are excited because it offers a novel way to potentially manage symptoms by focusing on the body's stress response, which is often overactive in scleroderma patients.

What evidence suggests that the Apollo Neuro Device is effective for managing symptoms of scleroderma?

Research has shown that the Apollo Neuro device, which participants in this trial may receive, might help alleviate anxiety and stress through gentle vibrations that calm the nervous system. These vibrations can enhance the body's ability to manage stress, potentially reducing fatigue and improving overall well-being. Although specific data on systemic sclerosis (SSc) is limited, the device's capacity to promote relaxation and reduce stress might aid in alleviating SSc symptoms such as fatigue and Raynaud phenomenon, where fingers and toes feel numb and cold. Early users have reported feeling calmer and more focused, suggesting the device could enhance quality of life.

Who Is on the Research Team?

RT

Robyn T Domsic, MD

Principal Investigator

University of Pittsburgh

Are You a Good Fit for This Trial?

This trial is for individuals with Systemic Sclerosis, a condition that causes hardening and tightening of the skin. Participants should experience fatigue and Raynaud's phenomenon, which involves poor blood flow to certain parts of the body like fingers and toes.

Inclusion Criteria

Baseline score ≥55 on the FACIT-Fatigue scale
Presence of Raynaud phenomenon with ASRAP-SF severity of T-score ≥40
Ability to provide written informed consent
See 4 more

Exclusion Criteria

Pregnant or breastfeeding women
I have diabetes.
I have not had major surgery in the last 8 weeks.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomized to receive either the Apollo Neuro device or a sham device, which they will wear daily for 6 weeks

6 weeks

Follow-up

Participants are monitored for changes in fatigue, Raynaud attacks, and quality of life after the treatment phase

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Apollo Neuro Device
Trial Overview The study is testing the Apollo Neuro Device, a wearable device designed to help manage symptoms related to Systemic Sclerosis. It will be compared against a sham (fake) device to see if it can improve fatigue and Raynaud's phenomenon.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Apollo Neuro DeviceExperimental Treatment1 Intervention
Group II: Sham DevicePlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Robyn T. Domsic, MD, MPH

Lead Sponsor

Trials
3
Recruited
200+

United States Department of Defense

Collaborator

Trials
940
Recruited
339,000+

Citations

Apollo Device for Fatigue in Systemic SclerosisApollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, ...
2.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/39617410/
Association of the Apollo Wearable With Fatigue, Raynaud ...Use of the Apollo wearable for 4 weeks was associated with improvement in fatigue and RP symptoms in patients with SSc, with improved QOL ...
The Apollo Device in Systemic Sclerosis for ...The purpose of this study it to test the efficacy of a wearable device to improve symptom management and maximize qualify of life in ...
Apollo Neuro ResearchAfter 4 weeks of using the Apollo wearable, participants reported less fatigue (p < 0.001). The average daily number of Reynaud attacks declined (p < 0.01), as ...
Evaluating the impact of Apollo Neuro™ wearable on ...Exploratory outcomes included changes in resilience and alcohol use behaviors, as measured by the Brief Resilience Scale (BRS) and the Alcohol ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security